See more : XIANGPIAOPIAO Food Co.,Ltd (603711.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Veru Inc. (VERU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Veru Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shenzhen SED Industry Co., Ltd. (000032.SZ) Income Statement Analysis – Financial Results
- Skipper Limited (SKIPPER.BO) Income Statement Analysis – Financial Results
- Liberty Defense Holdings, Ltd. (SCAN.V) Income Statement Analysis – Financial Results
- Harbin Electric Corporation Jiamusi Electric Machine CO.,Ltd (000922.SZ) Income Statement Analysis – Financial Results
- Zhejiang Tiantie Industry Co., Ltd. (300587.SZ) Income Statement Analysis – Financial Results
Veru Inc. (VERU)
About Veru Inc.
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.89M | 16.30M | 39.35M | 61.26M | 42.59M | 31.80M | 15.86M | 13.66M | 22.13M | 32.60M | 24.49M | 31.46M | 35.03M | 18.57M | 22.22M | 27.54M | 25.63M | 19.32M | 14.82M | 11.16M | 8.83M | 9.05M | 8.42M | 6.72M | 5.77M | 4.72M | 5.45M | 2.92M | 2.06M | 2.20M | 16.20M | 12.50M | 11.20M | 13.10M | 10.70M |
| Cost of Revenue | 11.03M | 8.73M | 8.76M | 13.33M | 11.81M | 10.15M | 7.08M | 6.64M | 8.78M | 13.63M | 11.37M | 13.95M | 14.41M | 8.70M | 9.30M | 14.03M | 14.90M | 12.16M | 9.33M | 6.37M | 5.21M | 5.46M | 4.86M | 5.34M | 3.60M | 3.31M | 5.27M | 3.48M | 3.68M | 2.50M | 7.50M | 6.90M | 6.10M | 7.20M | 6.10M |
| Gross Profit | 5.85M | 7.57M | 30.59M | 47.93M | 30.79M | 21.66M | 8.78M | 7.02M | 13.35M | 18.97M | 13.12M | 17.50M | 20.62M | 9.87M | 12.92M | 13.52M | 10.73M | 7.16M | 5.49M | 4.79M | 3.62M | 3.59M | 3.56M | 1.38M | 2.16M | 1.40M | 178.03K | -559.30K | -1.62M | -300.00K | 8.70M | 5.60M | 5.10M | 5.90M | 4.60M |
| Gross Profit Ratio | 34.67% | 46.43% | 77.73% | 78.24% | 72.28% | 68.10% | 55.36% | 51.40% | 60.33% | 58.18% | 53.58% | 55.65% | 58.86% | 53.14% | 58.16% | 49.08% | 41.86% | 37.04% | 37.03% | 42.93% | 41.03% | 39.67% | 42.31% | 20.52% | 37.49% | 29.70% | 3.27% | -19.18% | -78.50% | -13.64% | 53.70% | 44.80% | 45.54% | 45.04% | 42.99% |
| Research & Development | 12.81M | 51.20M | 70.65M | 32.69M | 16.94M | 13.74M | 10.85M | 3.50M | 99.39K | 219.82K | 5.58K | 4.75K | 5.28K | 10.93K | 381.00 | 105.92K | 284.22K | 208.61K | 210.88K | 273.78K | 179.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 361.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.02M | 8.66M | 12.13M | 9.14M | 7.49M | 9.63M | 6.23M | 6.43M | 7.01M | 7.04M | 5.89M | 4.82M | 5.71M | 4.46M | 4.89M | 4.93M | 1.85M | 2.97M | 3.14M | 2.90M | 3.04M | 2.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.27K | 88.87K | 0.00 | 58.12K | 221.72K | 52.95K | 332.76K | 220.18K | 191.15K | 223.80K | 179.87K | 218.50K | 123.10K | 47.60K | 36.53K | 43.83K | 129.16K | 0.00 | 0.00 | 433.82K | 1.64M | 2.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.07M | 8.75M | 12.13M | 9.20M | 7.71M | 9.68M | 6.56M | 6.65M | 7.20M | 7.26M | 6.07M | 5.04M | 5.83M | 4.51M | 4.92M | 4.97M | 1.98M | 2.97M | 3.14M | 3.33M | 4.68M | 5.97M | 8.00M | 10.70M | 8.10M | 6.20M | 7.10M | 3.70M |
| Other Expenses | -1.22M | 2.09M | -316.06K | -8.71M | 14.10M | -5.89M | -2.20M | 15.51M | 9.20M | 9.20M | 9.20M | 7.71M | 2.01M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 1.83M | 1.28M | 0.00 | 0.00 | 0.00 | 100.00K | 500.00K | 400.00K | 300.00K | 200.00K | 100.00K |
| Operating Expenses | 42.77M | 101.35M | 113.81M | 53.36M | 45.53M | 28.09M | 29.65M | 14.58M | 10.33M | 12.35M | 9.20M | 7.71M | 9.68M | 6.57M | 6.65M | 7.30M | 7.55M | 6.28M | 5.25M | 6.10M | 4.69M | 4.92M | 6.23M | 1.98M | 4.80M | 4.43M | 3.33M | 4.68M | 6.33M | 8.10M | 11.20M | 8.50M | 6.50M | 7.30M | 3.80M |
| Cost & Expenses | 53.80M | 110.08M | 122.58M | 66.70M | 57.34M | 38.24M | 36.74M | 21.21M | 19.11M | 25.99M | 20.57M | 21.67M | 24.09M | 15.27M | 15.94M | 21.33M | 22.45M | 18.44M | 14.58M | 12.47M | 9.90M | 10.38M | 11.09M | 7.32M | 8.41M | 7.74M | 8.60M | 8.15M | 10.01M | 10.60M | 18.70M | 15.40M | 12.60M | 14.50M | 9.90M |
| Interest Income | 0.00 | 0.00 | 4.37M | 4.89M | 4.62M | 4.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.17K | 55.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 607.47K | 2.43M | 4.37M | 4.85M | 4.62M | 4.71M | 2.95M | 2.04M | 3.32M | 0.00 | 50.57K | 0.00 | 296.18K | 124.63K | 3.98M | 2.39M | 0.00 | 74.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 268.18K | 269.87K | 209.60K | 593.87K | 783.64K | 471.42K | 452.05K | 481.01K | 422.87K | 494.26K | 589.34K | 556.30K | 461.45K | 464.91K | 466.54K | 268.38K | 217.09K | 252.94K | 333.63K | 522.80K | 1.09M | 1.55M | 1.01M | 923.92K | 1.83M | 1.28M | 533.99K | 553.30K | 675.08K | -100.00K | -500.00K | -400.00K | -300.00K | -200.00K | -100.00K |
| EBITDA | -36.20M | -89.98M | -79.23M | 9.75M | -14.65M | -7.14M | -19.67M | -8.12M | 4.92M | 7.11M | 4.51M | 10.35M | 11.40M | 3.76M | 4.69M | 5.32M | 3.40M | 1.01M | 573.99K | -1.11M | 19.17K | 210.53K | -1.66M | 321.06K | -812.89K | -1.74M | -2.73M | -4.76M | -7.10M | -8.30M | -2.20M | -2.50M | -1.10M | -1.60M | 800.00K |
| EBITDA Ratio | -214.38% | -552.10% | -211.47% | -38.93% | -34.62% | -20.24% | -131.57% | -44.52% | 16.22% | 21.64% | 18.77% | 33.21% | 31.65% | 18.08% | 39.04% | 26.99% | 9.08% | 6.19% | 3.96% | -6.94% | 0.94% | 2.33% | -4.75% | 2.98% | -16.61% | -39.07% | -50.15% | -163.37% | -340.18% | -377.27% | -13.58% | -20.00% | 8.93% | -12.21% | 7.48% |
| Operating Income | -36.92M | -93.78M | -83.22M | -5.44M | -14.75M | -6.44M | -20.87M | -8.49M | 3.02M | 6.62M | 3.92M | 9.79M | 10.94M | 3.30M | 4.35M | 4.72M | 3.18M | 875.91K | 240.36K | -1.31M | -1.07M | -1.34M | -2.67M | -602.86K | -2.64M | -3.03M | -3.15M | -5.24M | -7.95M | -8.20M | -1.70M | -2.10M | 1.30M | -1.40M | 900.00K |
| Operating Income Ratio | -218.61% | -575.46% | -211.47% | -8.88% | -34.62% | -20.24% | -131.57% | -62.20% | 13.64% | 20.30% | 16.02% | 31.12% | 31.23% | 17.75% | 19.57% | 17.13% | 12.42% | 4.53% | 1.62% | -11.75% | -12.09% | -14.76% | -31.72% | -8.98% | -45.75% | -64.17% | -57.80% | -179.62% | -385.12% | -372.73% | -10.49% | -16.80% | 11.61% | -10.69% | 8.41% |
| Total Other Income/Expenses | -160.93K | 1.11M | -316.06K | -8.71M | -5.31M | -5.89M | -2.20M | -108.38K | -204.60K | 68.63K | 33.28K | 144.26K | -147.91K | -63.37K | -125.03K | 332.10K | 1.02M | -7.00K | -12.35K | -44.40K | 0.00 | 0.00 | -1.26M | -568.40K | 145.20K | 100.18K | 117.14K | 79.53K | -252.61K | 0.00 | 1.00M | 0.00 | 600.00K | 400.00K | 200.00K |
| Income Before Tax | -37.08M | -92.67M | -83.54M | 4.27M | -20.05M | -12.32M | -23.07M | -8.60M | 2.81M | 6.69M | 3.96M | 9.93M | 10.79M | 3.23M | 4.22M | 5.05M | 4.20M | 868.91K | 228.01K | -1.33M | -1.07M | 0.00 | -3.93M | -1.17M | -2.49M | -2.93M | -3.03M | -5.16M | -8.20M | 0.00 | -1.50M | 0.00 | -800.00K | -1.00M | 1.00M |
| Income Before Tax Ratio | -219.56% | -568.65% | -212.28% | 6.96% | -47.08% | -38.74% | -145.43% | -63.00% | 12.72% | 20.51% | 16.16% | 31.58% | 30.80% | 17.41% | 19.01% | 18.34% | 16.40% | 4.50% | 1.54% | -11.87% | -12.09% | 0.00% | -46.67% | -17.44% | -43.23% | -62.05% | -55.65% | -176.89% | -397.36% | 0.00% | -9.26% | 0.00% | -7.14% | -7.63% | 9.35% |
| Income Tax Expense | 725.10K | 480.21K | 236.40K | -3.13M | -1.08M | -303.93K | 866.10K | -1.99M | 2.47M | 2.34M | 1.52M | -4.41M | -4.51M | -2.17M | -2.51M | -1.49M | -762.86K | -825.00K | -29.32K | 58.51K | 1.02M | 1.04M | 2.07M | 447.43K | 906.65K | 624.13K | 89.28K | 291.21K | 963.00K | 100.00K | 1.30M | 1.60M | 5.60M | 100.00K | 600.00K |
| Net Income | -37.80M | -93.15M | -83.78M | 7.39M | -18.97M | -12.02M | -23.94M | -6.61M | 344.73K | 4.35M | 2.43M | 14.34M | 15.30M | 5.40M | 6.74M | 6.54M | 4.97M | 1.69M | 282.03K | -1.36M | -2.02M | -2.37M | -3.48M | -1.17M | -3.69M | -3.75M | -3.36M | -5.61M | -8.66M | -8.30M | -3.00M | -3.70M | -4.30M | -1.50M | 300.00K |
| Net Income Ratio | -223.86% | -571.60% | -212.88% | 12.07% | -44.55% | -37.79% | -150.89% | -48.42% | 1.56% | 13.33% | 9.93% | 45.59% | 43.67% | 29.08% | 30.32% | 23.73% | 19.38% | 8.77% | 1.90% | -12.15% | -22.87% | -26.20% | -41.36% | -17.44% | -63.99% | -79.53% | -61.59% | -192.33% | -419.54% | -377.27% | -18.52% | -29.60% | -38.39% | -11.45% | 2.80% |
| EPS | -0.28 | -1.10 | -1.05 | 0.10 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.09 | 0.51 | 0.55 | 0.20 | 0.25 | 0.25 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| EPS Diluted | -0.28 | -1.10 | -1.05 | 0.09 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.08 | 0.50 | 0.53 | 0.19 | 0.24 | 0.24 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| Weighted Avg Shares Out | 134.88M | 84.97M | 80.12M | 76.27M | 66.75M | 63.32M | 53.86M | 34.41M | 28.67M | 28.53M | 28.52M | 28.38M | 27.69M | 27.29M | 26.98M | 25.65M | 26.12M | 24.95M | 23.80M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
| Weighted Avg Shares Out (Dil) | 134.88M | 84.97M | 80.12M | 83.80M | 66.75M | 63.32M | 53.86M | 34.64M | 28.93M | 28.92M | 28.87M | 28.73M | 28.93M | 28.97M | 28.55M | 27.81M | 27.98M | 26.40M | 26.49M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
Veru Inc. (VERU) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VERU's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 --
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
What Makes Veru (VERU) a New Buy Stock
Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Veru Reschedules Annual Meeting of Shareholders
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings--
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today...
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS),...
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today...
The 3 Best Penny Stocks to Buy in February 2024
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of companies that make life in...
Source: https://incomestatements.info
Category: Stock Reports